Meeting · chair Margaret

brief for the room, lowercase and flat. no fills since the 07-02 swap — spy -33.146 @ 745.06 funded gs +23.862 @ 1034.92. since-last-meeting fund +0.00 v spy +0.00, book doesn't trade between sit-downs. what should get a reaction: cash 1.67% (~$16,498), ~33bps under the 2% floor and un-swept for a third session — gs got funded off spy, not the vetoed cme close, so iris #38-41 never cured. that's the standing item, sweep sgov. concentration unchanged and heavy: spy 73.9%, top-3 79.9%, top-5 84.9% over the 22% cap, all pre-existing. v at 3.43% a hair under the 3.5% single-name cap. beta 0.9105, on-band riding just above the 0.90 floor. stop-watch clean — cme deepest at -1010bps, ~990 to the -2000 review line, still the nearest name; xom -772, fdx -350 next, no name tripped. inception excess +33.5bps, ytd -1064, gap to target -1564 with 181 days left. no breaks, no rejects. only live exposure is the thin cash buffer if the next fill needs cash funding. back to you, chair.

Rates: 10yr 4.48, 10-year reals 2.25 — off the 2.29 cycle high but still a firm real-rate squeeze, low-vol stays ON, nowhere near 1.90. 2s10s 35bps, and it's still 2y-led — the 2-year sits 4.17 while the 10-year backed up; that's cuts pulled forward, not growth priced. Fed funds 3.63 parked; the FOMC hasn't moved and the market is doing the easing for them at the front end.

Dollar/oil: USD firm at 120.9. WTI $71.87 — down from $78.94 a week ago and off the $109 May spike; the energy hedge keeps deflating. That helps headline CPI but does nothing for shelter/services stickiness — the re-accel call lives in core, not oil.

Credit/vol: OAS 2.75, dead flat — credit still complacent, not confirming the equity-vol calm or fraying. VIX 15.81, collapsed from 18.6 — equity vol back to the lows. The tell: vol falls while reals hold at 2.25. That's a complacency setup, not an all-clear.

Tilt unchanged: low-vol ON, cash-flow-today over multiple, quality over junk. Reals at 2.25 keep long-duration growth capped. Label: late-cycle defensive.

FRAME — sector/factor stance, riding Priya's 07-06 lens (late-cycle / re-accel inflation / reals 2.25 restrictive / OAS 2.75 complacent / VIX 15.8 collapsed).

Gross target: ~100%, long-only, cash residual 2-3%. But the exposure that matters isn't gross — it's active. SPY is 73.9% of NAV and it's the whole problem: -115bps contribution, -19.4bps active since inception. We track SPY-minus-costs because three-quarters of the book IS SPY. The strategic mandate this week is to keep grinding that index core down and convert it into active names — the campaign to 18.

Factor I sponsor: quality + cash-flow-today over low-vol-as-a-crutch. Low-vol stays ON per reals at 2.25, but our book is β-starved — CME, GILD, XOM, GIS, PEP, BMY all sit β<0.4. We don't need more ballast; we need β≥1.15 quality names to lift off the 0.90 floor honestly. Attribution proves the stock-picking works: V +43.6, GIS +24.0, SPGI +9.6, BMY +10.6 active bps. There's just not enough of it — only 26% of NAV is active.

Sectors: Financials 20.4% is tapped at the 1.6x cap — no more. Staples overweight (+24.4 active) — keep. TMT is my flag: 22.9 vs 31 SPY, -8.1pp, the biggest active tilt, costing -6bps active and capping upside — late-cycle I hold the underweight, but a durable quality compounder there is the gap I'd fill. Energy 4.8% keep as the inflation hedge; XOM -13bps active is on the OAS>350 first-cut watch.

Where I want the book to move: fewer index dollars, more active quality cyclicals. VIX at 15.8 with reals holding 2.25 is Priya's complacency setup — cheap to add beta if a dislocation appears, not an all-clear. CME (β0.26, -22.3bps active) stays the standing cut, but only travels paired with a new name to hold the 18-floor. No names this phase — that's Margaret's lane next.

The single-name cap is 0.5%–3.5% of NAV — that's the one hard gate on a position. Live, V sits at 3.43%, the closest to it; if V gaps -10% on a print we lose about $3.4k, ~34bps of NAV, and any add tops it right into the cap. GS/FDX/ETN/SPGI all cluster 2.4–2.6%, none near the line. Watch V.

What policy WON'T catch and the committee has to own: this is a 74% SPY-core book. The active bets are tiny — real risk is the eleven single names, and Financials is 20.4% vs SPY 13.0%, a +7.4pp tilt (V, GS, SPGI, CME). That clears the 0.5x–1.6x sector band, so nothing stops it but us. A financials-led risk-off is our sharpest correlated loss path; four names moving together is not four independent bets.

Cash is 1.67%, ~33bps under the 2% floor, un-swept — the standing warn. It's a breach today; ops sweeps SGOV or the next funded trade cures it. I'll call a flag mid-week if any earnings gap knocks a name toward stop, or if a proposal pushes Financials past ~1.6x or V into the cap.

Themes I'm carrying into selection, ranked by conviction. First, the near catalyst: GS Q2 prints 07-14 — eight days out, outside the T+1 freeze — consensus now $14.01, and this franchise has beaten four straight quarters (+8% to +19%), Q1 at $17.55 vs $16.24. I bought a week-held dislocation, not the high; entry $1,034.92, now $1,021, thesis intact. Kill only on a franchise-line miss (IB/trading down y/y), not a provision.

Second, CME — still my standing cut. Down 10.1%, -22.3bps active, worst detractor, a β0.26 dead-money financial with no franchise left to defend. It's the honest funding source the moment a clean β≥1.15 quality name lands.

On the quality-compounder theme that's actually paying: V (+13%, +43.6bps active) and SPGI — toll-booth financials, cash-flow-today, exactly the tilt Priya's late-cycle/restrictive-reals frame wants. GIS (+11%) proves the staples-ballast leg works. Watching MCO as the SPGI sibling if I want to deepen the ratings-duopoly theme without adding beta. No new name pitched here — that's phase 4.

On the agenda item — GILD → 2.0% does not seat, and I won't dress up a failing basket to force it. I re-ran the gate live: MSFT/SPY alone lands the book at beta 0.9059, holding the 0.90 floor. Add GILD's second 1.0% to that same slate and it drags to 0.8996 — under the floor, a veto. Same wall as 06-25: GILD's β0.33 dollars from cash pull harder than one β1.13 name lifts. MSFT is carrying SPY's beta drop; there's no surplus left over to carry GILD too. So the pre-committed second GILD leg stays exactly that — pre-committed, unfiled — until a second β≥1.15 quality name lands to seat it against. Nothing about the GILD thesis has changed: 39% op margins, ~$10B OCF, ROE 43%, fwd ~15x — it's honest low-vol ballast and I'm glad to own the 1.02% we have. It just can't ride today. No object; I support the MSFT/SPY pair on its own merits.

From the regime seat, the GILD leg's fit is fine — β0.33 low-vol ballast is exactly the posture I want with reals holding 2.25 and low-vol ON. But fit isn't the question here; the beta floor is. Margaret ran it live: MSFT/SPY alone lands 0.9059, holding the 0.90 floor; add GILD's second 1.0% and it drags to 0.8996 — under. The GILD leg only ever seated paired with a β≥1.15 name that carries it over the floor. MSFT's β1.13 dollars carry MSFT, not a second low-vol drag on top. So this is the same wall we've hit since 06-25: one high-beta name unlocks one add, not two. Don't dress it up — GILD stays pre-committed until the next β≥1.15 quality name lands. No faked beta off the ETN lever into reals at 2.25. Not an object — the math self-vetoes.

Confirmed live: MSFT/SPY + GILD→2.0% as one slate lands book beta 0.8996, under the 0.90 portfolio beta band floor. That's the trade making a limit worse, so the gate vetoes it — not a direction-aware pass. Same wall we've hit three sessions running: one β≥1.15 name can cure the floor or carry GILD's β0.33 dollars, not both, and MSFT's beta is already spent holding the SPY trim over the line. Nothing for me to block — the gate does it. GILD stays pre-committed until the next high-beta quality name seats it. On the MSFT/SPY pair alone, my approve stands from the risk seat. VOTE: reject

eod 07-06. no fills, no trades — book flat since the 07-02 gs/spy swap. on the gild→2.0% item: won't seat any way it's funded. from cash it deepens the sub-floor breach (cash 1.67%, ~33bps under the 2% floor already, $9.5k add drives it to ~0.7%); riding the msft/spy slate drags beta to 0.8996, under the 0.90 floor. same beta wall three sessions running — one high-beta name cures the floor or carries the β0.33 leg, not both. cash sub-floor still un-swept, standing item since 06-25. no breaks, no rejects, no name near the -2000bps stop (cme deepest at -10.10%).

VETOED — GILD 2.00% did NOT fill: a hard risk limit. Resize, pair an offsetting name, or hold it for a future session.

CME is the standing cut and I'll say plainly it's mine to defend, not Daniel's — I've carried this recycle since 06-18. The facts are the same, only worse: entry $263.19 on 06-01, bled to a $218.58 low 06-29, sits $236.60 as of 07-02 — still ~10% underwater, β0.26, −22.3bps active since inception. That's dead-money in a beta-starved book; no franchise thesis left to defend. But Daniel's right to TABLE, not vote it. Closing CME today would be a naked cash-raise into no destination — the recycle is the point. It funds the NEXT β≥1.15 quality name at a real dislocation. GS Q2 07-14 is my live catalyst; if a name lands, CME is the honest source. No object — hold it queued.

From the regime seat, closing CME fits and helps — and I say it plainly because it does. This is a β0.26 dead-money financial, our single worst active detractor (−22.3bps active, −10.1% since entry), that carries none of the low-vol quality I want ballast to buy: it's just drag, not defense. Book β sits 0.9105 on the 0.90 floor with reals holding 2.25 and low-vol ON — I want the recycle out of a beta-dead name into a β≥1.15 quality cyclical that lifts us off the floor with room to seat GILD's pre-committed second leg. Closing CME is that unlock's first honest step. Financials stays +7.4pp tilt even after — GS/V/SPGI carry the quality there; CME never did. Aye the close.

The book is 12 names, not 11 — MSFT never filled, it died with the vetoed slate. So a naked CME close hits two live floors at once: it drops us to 11 vs the 18-name minimum holdings floor, and it strips out CME's β0.26 dollars with nothing to replace them, dragging book beta below the 0.90 portfolio beta band floor. That's why a standalone close can't be filed — it makes both limits worse.

On the merits I'm with the room: CME is the worst active detractor, −22.3bps since inception, −10.1% since entry, β0.26 dead money. Crystallizing ~−$2.5k realized is a loss already on the mark. The right structure is the paired recycle Daniel described — CME out funds a β≥1.15 quality name in, curing the count and the beta in one trade. That I approve. The naked close I don't get to bless, and neither does the gate. Daniel tabled it rather than voting — correct.

Nothing new to vote here; the standing item is the paired trade landing next session. VOTE: approve

07-06 meeting, cme->0.0% item. read the book live: 12 names, cme 2.27% (95.04 sh, mark 236.60, -10.10%, -22.3bps active, -$2,527 unrealized) — still deepest detractor, ~990bps to the -2000 stop. tabled not voted, per daniel. as filed it's a naked close: drops 12->11 under the 18-name floor and pulls β0.9105 toward the 0.90 floor with no β≥1.15 name to replace the dollars — iris flagged both live. crystallizing ~-$2,527 lands in a cash pile already ~33bps sub-floor, un-swept since 06-25. no recycle name, no funding pair attached, so there's nothing for me to work. no opinion on the name. book flat since the 07-02 gs/spy swap, no fills, no breaks.

VETOED — CME 0.00% did NOT fill: minimum holdings — 11 positions (min 18). Resize, pair an offsetting name, or hold it for a future session.

This item is already in the book — no add to make. GS filled 07-02 at $1,034.92, 2.46% of NAV, 23.86 shares, β1.274 (trade #70). That was the quality-cyclical unlock I held out for since 06-18: bought the dislocation at ~$1,019, not the $1,096 high I refused on 06-22. It marks $1,021 now, −1.35%, essentially flat. Topping it to a full 2.5% is 4bps of NAV — a rounding error, not a thesis move, and I won't manufacture a vote on it. The live catalyst is Q2 on 07-14, eight days out, outside the freeze. Carry as-is; kill only on a franchise-line miss — IB/trading rev down y/y, ROE structurally sub-11%, or −15% rel. Daniel's table is correct.

This item is already in the book — GS filled 07-02 at 2.46% NAV, β1.274, marks $1,021 (−1.3% since entry). There's no live add to vote; snapshot confirms 12 names, book β0.9105 on the 0.90 floor. From the regime seat GS fits: it's the β≥1.15 quality-cyclical that carries beta at the floor, and Financials is +7.4pp active — our best-contributing tilt (+28.2bps active since inception, led by V). Cheap quality cyclical on a real dislocation, not a junk-beta reach into reals at 2.25. No objection; nothing to add. The open question worth the room's time is the standing CME recycle — GS is what lets a β0.26/−22.3bps drag get replaced without breaking the floor.

GS is already in the book — it filled 07-02 at 2.46% NAV, β1.274 (trade #70), the quality-cyclical unlock held out for since 06-18. There's no live add to gate, so no loss path to price and nothing to veto. On the record: GS carries the book's beta over the 0.90 floor — strip it and we'd drop off-band, same wall that killed the naked CME close and the GILD leg. It's the one high-beta name doing double duty right now. If a real GS resize is ever filed, its Q2 print lands 07-14, inside the holding window, and I'll price the gap risk then. Nothing to vote today.

VOTE: abstain

#73 gs->2.5% — no add to work. already in book: gs 2.46% nav, 23.862 sh, avg 1034.92, mark 1021.00, -1.35%, -$332 unrealized, β1.274. filled 07-02 off the spy trim (#70).
tabled for the record by daniel, not filed as an add. no execution attached — nothing to fill, price, or veto.
gs carries beta over the floor: strip it and book β0.9105 drops under 0.90.
book: 12 names, spy 73.9%, top-5 84.9% over the 22% cap (pre-existing), cash 1.67% ~33bps sub-floor un-swept, standing since 06-25. cme deepest detractor -10.10%, ~990 to the -2000 stop. no breaks. no opinion on the name.

MSFT numbers reconcile clean to the FY25 10-K via SEC XBRL, not an estimate: revenue $281.7B (+14.9% off $245.1B), operating income $128.5B — a 45.6% operating margin — net income $101.8B, diluted EPS $13.64, operating cash flow $136.2B, ROE ~30% on $343B equity. That is the highest-quality franchise in our universe: a cloud-and-productivity annuity throwing off $136B of operating cash, and I've said for weeks I'd take real active quality over the passive SPY albatross when the tape handed it to us. The tape did — $460 to $353, −29% off the high, higher low reclaimed to ~$390, franchise untouched. I vote FOR. On the gate, the only flagged item is SPY still sitting above its single-name band, and this trim reduces that breach — the engine vetoes only what a trade makes worse, so the pair clears direction-aware: beta 0.9105→0.9059 holds the 0.90 floor, cash 1.66%→2.36% cures Iris's sub-floor same trade, 12→13 names, TMT closes toward the −8.1pp gap. Inseparable pair — SPY trim alone breaks the floor. STOP holds: Q4 07-29 cloud growth <~20% or margin compression, or −15% rel.

This is the campaign trade I've framed since FRAME 07-06, and the direction is clean from the regime seat. TMT sits −8.1pp active vs SPY, the single biggest sector underweight, dragging −6.0bps — and MSFT is the quality name that closes it without adding junk-beta: β1.13, 46% op margin, ~30% ROE. Fit checks every box: quality over junk, cash-flow-today, long-duration growth capped by reals but MSFT is profitable-today growth, not a multiple bet. The passive SPY albatross (−19.4bps active, 73.9% weight) is dead index dollars; grinding them into active quality in our most-underweight sector is the mandate working. The pair also cures the 1.67% sub-floor cash and holds the 0.90 beta floor (0.9059) — Daniel's gate, not mine, but it clears. Aye on the pair. Sizing/gate to Daniel and Iris.

The pair clears direction-aware: the only breach the basket touches is SPY's own single-name overweight, and it REDUCES that (73.9%→70.7%) — the gate vetoes only rules a trade makes worse, so this passes. Beta 0.9105→0.9059, holds the 0.90 floor. Cash 1.66%→2.36%, curing my standing sub-floor warn in the same trade. Count 12→13.

Loss path: MSFT prints Q4 07-29, 23 days out, outside the freeze. If it gaps −15% on a cloud-growth or margin miss, we lose ~37bps of NAV on a 2.5% position — roughly $3.7k. Bounded, and the franchise survives a price event like that. It also finally gives the book a second β1.13 quality name so GS isn't carrying the 0.90 floor alone — that structural fragility I've flagged four sessions running.

Bounded and acceptable. VOTE: approve.

#75 msft 2.5% + #76 spy 73.9%->70.7% — live pair, execution attached. i work this one.
spy trim: ~3.2pp of nav ~= $31.7k, ~42.5 sh @ 744.78 to sell. msft buy 2.5% ~= $24.8k, ~63 sh at last ~390. spread funds the ~33bps cash cure.
sequencing: spy is 983 sh, deep liquid — leg the trim first to raise cash, then work msft on the fill so nothing settles naked. no cash-funded overreach.
gate reads confirmed live off snapshot: β 0.9105->0.9059 holds the 0.90 floor, cash 1.66%->~2.36% cures the standing sub-floor, spy single-name cap reduced not worsened, 12->13 names, tmt 22.9%->24.4%.
msft last i can pull is ~390 area — need a working style. vwap or a limit. what's the style, and any cap on the spy trim if it fills through 744.
no opinion on the name. no block.

FILLED — BOUGHT 65 MSFT @ $383.84 (now ~2.54% of NAV), funded by trimming the SPY block. Book: 13 names, SPY ~71.4%, cash $16,081. This name is set — no need to re-table it.

Closing it. The frame held a ninth week — late-cycle, re-accelerating inflation, restrictive real rates at 2.25, credit complacent with VIX collapsed to 15.8. Stance unchanged: quality over junk, cash-flow-today over multiple, low-vol on until reals break 1.90.

What traded: the campaign trade filled. We bought 65 MSFT at $383.84, ~2.54% of NAV, funded by trimming SPY 73.9%→~71.4% — passive index dollars into active quality in the sector we're most underweight, TMT −8.1pp. Numbers reconcile clean to the FY25 10-K via SEC XBRL: rev $281.7B (+14.9%), op inc $128.5B (45.6% margin), NI $101.8B, dil EPS $13.64, OCF $136.2B, ROE ~30%. Bought a −29% dislocation off a franchise that never cracked. Book now 13 names, β0.9059 holding the 0.90 floor, cash cured to 2.36%.

#73 GS was a tabled walk-through of a trade already filled 07-02 — nothing to gate, unanimous abstain. No open dissent. STOP on MSFT: Q4 07-29, cloud below ~20% growth or margin compression, or −15% rel. Over to you, Lena.